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Rotavirus is the most common cause of severe infant and childhood diarrhea worldwide,
and the morbidity and mortality rate is going to be outnumbered in developing countries
like Bangladesh. To mitigate this substantial burden of disease, new therapeutics such as
vaccine and drug are swiftly required against rotavirus. The present therapeutics insight
study was performed with comprehensive immunoinformatics and pharmacoinformatics
approach. T and B-cell epitopes were assessed in the conserved region of outer
capsid protein VP4 among the highly reviewed strains from different countries including
Bangladesh. The results suggest that epitope SU1 (TLKNLNDNY) could be an ideal
candidate among the predicted five epitopes for both T and B-cell epitopes for the
development of universal vaccine against rotavirus. This research also suggests five
novel drug compounds from medicinal plant Rhizophora mucronata Lamk. for better
therapeutics strategies against rotavirus diarrhea based on 3D structure building,
pharmacophore, ADMET, and QSAR properties. The exact mode of action between drug
compounds and target protein VP4 were revealed by molecular docking analysis. Drug
likeness and oral bioavailability further confirmed the effectiveness of the proposed drugs
against rotavirus diarrhea. This study might be implemented for experimental validation
to facilitate the novel vaccine and drug design.
Keywords: human rotavirus, diarrhea, pharmacoinformatics, immunoinformatics, vaccine design, drug
development
INTRODUCTION
Diarrhea caused by rotavirus is accountable for 500,000 deaths with 2.4 million hospitalizations
among children under the age of 5 years in every year throughout the world (Parashar et al., 2003,
2006, 2009). It is therefore to be noted that around 85% of them live in developing countries (World
Health Organization, 2008). Ruth Bishop identified this virus in 1973 from the small intestine’s
epithelial cells of children who are affected by diarrhea (Bishop et al., 1974). Humans are mainly
infected by species A, B, and C among the available eight species (A, B, C, D, E, F, G, and H) but
more than 90% of diarrheal infections occurred by species A. The exact mechanism of rotavirus
infection within the public health community is relatively unknown in causing of diarrhea (Rodrigo
et al., 2010), particularly in developing countries (Simpson et al., 2007). Rotavirus plays a myriad
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role in account of 37% of diarrhea related deaths in which 5%
occurred <5 years of age (Tate et al., 2012). It is noticeable that
the hospitalization rate of boys is twice than the girls (Ryan et al.,
1996; Rheingans et al., 2012). The rotavirusmostly prefer to infect
during cool and dry seasons (Levy et al., 2009; Atchison et al.,
2010). Rotavirus infection shows the climate variability that peaks
in winter to cause diarrhea. Comparatively, less infection rate
was recognized in temperate regions like United States (Glass
et al., 1996), Japan (Konno et al., 1983; Nakagomi et al., 2005),
northern Asian regions (Bresee et al., 2004), temperate regions in
Australia (Bishop et al., 2001), and Europe (Cook et al., 1990).
But, the southern Asian regions like Bangladesh is recognized
as fertile area to infection of rotavirus as it has the tendency
to occur all year round (Stoll et al., 1982). In 1981, Colorado
was badly affected by an outbreak of rotavirus A through
contaminated municipal water (Hopkins et al., 1984). In 2005,
Rotavirus was responsible for the largest epidemic of diarrhea in
Nicaragua, associated with mutations in the rotavirus A genome,
thereby escaping the virus release to the prevalent immunity in
the population (Bucardo et al., 2007). In 1977, a similar large
outbreak was also appeared in Brazil (Linhares et al., 1981).
Rotaviral genome, shelled with three protein (a core, inner
membrane, and outer capsid), contains 11 segmented gene
(double stranded; Gentsch et al., 1996). The both structural
protein (VP1–VP4, VP6, VP7) and non-structural protein
(NSP1–NSP4) are encoded by rotaviral each RNA gene segment,
but only gene segment 11 code for NSP5 and NSP6. The
outer shell that is used to characterize the rotavirus strain,
formed by VP7 (a glycoprotein-G protein) and VP4 (a protease-
cleaved protein—P protein). The combination of G and P
proteins is mediated by VP4 and VP7 structural protein due
to its independent nature of segregation both in vivo and
in vitro. And more than 80% of severe rotavirus disease is
caused by the mostly common four combinations (P[8]G1,
P[4]G2, P[8]G3, P[8]G4) of G and P proteins (Matthijnssens
et al., 2009). It is suspected that clinical protection probably
involves mucosal (intestinal), systemic antibody response, and
cell-mediated immunity however it is difficult to realize the
mechanisms, protection as well as duration of protection against
rotavirus infection (Santos and Hoshino, 2005; Kang et al., 2009).
Vaccinomics is the integration of immunogenetics and
immunogenomics with bioinformatics for the development of
vaccines (Poland et al., 2009). This method has been exclusively
used for the development of new vaccines based on the
bioinformatics. With the current advancement in the genome
sequencing and protein sequence databases, the rapid in silico
Abbreviations: CADD, Computer Aided Drug Design; Con., Conduritol;
3D, three dimensional; PDB, Protein data bank; ADME/Tox, Absorption,
Distribution, Metabolism, Excretion, Toxicity; LogS, Logarithm of solubility;
cLogP, Logarithm of partition coefficient; TPSA, The polar surface area. QSAR,
Quantitative structural activity relationship; HIA, Human Intestinal Absorption;
Vd, Volume of Distribution; UniPortKB, UniProt Knowledge Base; CTL,
Cytotoxic T-lymphocyte; IC50, half-maximal Inhibitory Concentration; MHC,
Major Histocompatibility Complex; IEDB, Immune Epitope Database; TAP,
Transport Associated Proteins; ACToR, Aggregated Computational Toxicology
Resource; admetSAR, absorption, distribution, metabolism, excretion, and toxicity
Structure-Activity Relationship database; nM, Nanomolar; nm, Nanometer; MSA,
Multiple Sequence Alignment.
informatics-based approach have obtained huge acceptance over
the traditional time consuming process (Flower, 2008). For
combating a number of life-threating diseases like multiple
sclerosis (Bourdette et al., 2005), malaria (López et al., 2001), and
tumors (Knutson et al., 2001) vaccinomics already demonstrated
its potentials.
To mitigate the threat of re-infection of diseases both humoral
and cell mediated immune response can play crucial role in this
perspectives. It is therefore necessary for an ideal vaccine to
stimulate a specific immunological response (Atanas and Irini,
2013). In this case, the identification of B-cell and T-cell epitope
can be effective to elicit immune response which can further
reinforce the possibility of novel vaccine design.
Computational tools and software, and drug–protein
simulation analysis have become very dependable and powerful
methods in the drug designing studies. These analysis can
significantly contribute to find out exclusive binding sites as
well as to determine suitable inhibitors to the target proteins,
respectively. Inhibitor molecules of envelope protein in dengue
virus were successfully identified by utilizing such types of
methodology (Yennamalli et al., 2009).
In our study, for the prediction of an ideal candidate for
vaccine development we have identified the conserved region
of the VP4 protein of Human rotavirus A and suggested
a potential T-cell and B-cell epitope by immunoinformatics
approach. Furthermore, drug discovery approach has also been
conducted to identify the most suitable drug compounds and to
stimulate the inhibition of the target site by natural medicinal
plant compounds using computational methods. This study has
been conducted with an aim to facilitate further laboratory
research for the complete treatment and prevention of diarrhea
caused by Human rotavirus A.
MATERIALS AND METHODS
The outline of this study was shown in Figure 1.
Retrieving VP4 Protein Sequences of
Human Rotavirus A
Twenty-four outer capsid VP4 protein of human rotavirus
A of different strains from 14 different countries specifically
Bangladesh, United States, United Kingdom, Australia, Italy,
Belgium, Venezuela, Israel, Philippines, Thailand, Sweden,
Japan, Indonesia, and India were retrieved from UniProt
Knowledge Base (UniProtKB) database (http://www.uniprot.org;
Apweiler et al., 2004; The UniProt Consortium, 2014) and
NCBI (http://www.ncbi.nlm.nih.gov/). The retrieved sequences,
which are highly reviewed and manually annotated, were
then stored in FASTA format for the immunoinformatics and
pharmacoinformatics elucidation.
Divergence Analysis and Conserved
Region Identification
CLC Sequence Viewer v7.0.2 (http://www.clcbio.com) from CLC
drug discovery workbench was used for the analysis of the
divergence among the different strains of the outer capsid
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FIGURE 1 | Schematic presentation of vaccine and drug designed against human rotavirus.
protein VP4.BioEdit v7.2.3 sequence alignment editor (Hall,
1999) was used through multiple-sequence alignment (MSA)
with ClustalW (Thompson et al., 1994) to identify conserved
sequences of different strains.
Identification of Protein Disorder Region
Globplot 2.3 (http://globplot.embl.de/) was used to identify
the protein disorder region of the VP4 protein of human
rotavirus A.
Structure Analysis of VP4 Protein
The automated protein modeling program MODELLER 9v11
(Šali et al., 1995) through HHpred (Söding, 2005; Söding et al.,
2005) was used to predict the 3D structure of VP4 protein
by satisfying spatial restraints. The evaluation tools ProCheck
(Laskowski et al., 1993) and Verify3D (Eisenberg et al., 1997)
were applied to assess the predicted three-dimensional model of
VP4 protein of Human Rotavirus A.
Vaccine Design
Determination of Highest Antigenic Conserved
Region
The antigenicity of the conserved region was determined by the
VaxiJen v2. 0 (Doytchinova and Flower, 2007) server in which the
default parameters was used for the identification.
Prediction of T Cell Epitope
To identify cytotoxic T lymphocyte (CTL) epitopes from themost
antigenic conserved region a server entitled NetCTL 1.2 (http://
www.cbs.dtu.dk/services/NetCTL/), was used which is based on
neural network architecture.
The possible epitopes were predicted by the in vivo peptides
processing which utilize 12 HLA-I super types (A1, A2, A3,
A24, A26, B7, B8, B27, B39, B44, B58, and B62; Larsen et al.,
2005). To generate more epitopes from the conserved region
the threshold value 0.5 was used to maintain specificity as well
as sensitivity. The epitopes were considered for the vaccine
development based on total high score combining from MHC
class I binding, transporter of antigenic peptides (TAP) transport
Frontiers in Pharmacology | www.frontiersin.org 3 June 2016 | Volume 7 | Article 153
Hossain et al. Vaccine and Drug Design against Diarrhea
efficiency, and proteosomal cleavage. Stabilized Matrix Method
(SMM; Peters and Sette, 2005) was employed to determine the
half-maximal inhibitory concentration (IC50) values of peptides
to the binding on MHC-I molecules. A web-based tool was used
to predict proteasomal cleavage, TAP transport, and MHC-I for
the selected epitopes (Tenzer et al., 2005). The TAP transport,
MHC-I binding and proteasomal processing produce an overall
score for each individual peptidases a T cell epitope. SMM was
also implemented for the prediction of MHC-II molecules that
cover the best candidates epitope from the conserved region.
Analyzing Epitope Conservancy
IEDB analysis resource (Bui et al., 2007) was used to analyze the
epitope conservancy for each individual predicted epitopes. The
given protein sequences were searched in this web based tool
for identities to calculate the conservancy level of all predicted
epitopes.
Population Coverage Prediction
IEDB population coverage calculation tool (Bui et al., 2006)
was used for the selection of population coverage of each
individual epitope. To predict the population coverage for the
corresponding epitope the allelic frequency of the interacting
HLA alleles were used.
Design of Epitope Structure
PEP-FOLD (Thevenet et al., 2012) server, which is a de novo
approach designed to predict peptide structures from amino
acid sequences was employed to build the three dimensional
(3D) structure of the highest conserved T-cell epitope SU1.
Consequently, the best model was selected from the proposed
five model to analyze the interactions with HLAs (HLA-I and
HLA-II).
Docking Simulation Study
AutodockVina (Trott and Olson, 2010) was employed to observe
the binding affinity between proposed interactingHLAmolecules
and SU1 epitope. HLA-B∗15:01 from HLA-I and HLA-DR from
HLA-II were selected for the binding analysis. The 3D crystal
structure of HLA-B∗15:01 named 1XR8 and HLA-DR named
1D5M were retrieved from RCSB (Research Collaboratory for
Structural Bioinformatics) database (Berman et al., 2005). Before
performing the docking study, 1XR8 and 1D5M were subjected
to Discovery studio (Van Joolingen et al., 2005) to remove the
ligand which made complex with HLA molecules.
Identification of the B Cell Epitope
Identification of the probable immunogenic epitopes in a
antigenic protein sequence could offer the reduction of wet lab
analysis for vaccine study. To initiate an immune response B-cell
epitope plays a crucial role by interacting with the B lymphocytes
(Nair et al., 2002). IEDB tools were utilized to identify essential
properties of the B cell antigenicity, including the Kolaskar
and Tongaonkar antigenicity scale (Kolaskar and Tongaonkar,
1990), Emini surface accessibility prediction (Emini et al., 1995),
Karplus and Schulz flexibility prediction (Karplus and Schulz,
1985), Bepipred linear epitope prediction analysis (Larsen et al.,
2006), and Chou and Fasman beta turn prediction analysis (Chou
and Fasman, 1978; Rini et al., 1992; Yamin et al., 2002). The
hydrophilicity of the predicted epitopes was also analyzed by
utilizing the Parker hydrophilicity prediction tool (Parker et al.,
1986) of Immune Epitope Database (IEDB) in which default
threshold was used.
Drug Development
Selection of Medicinal Compounds
Primarily, literatures were searched in NCBI (http://www.
ncbi.nlm.nih.gov), Pubmed (www.ncbi.nlm.nih.gov/pubmed),
and Google Scholar (http://scholar.google.com/) for the
identification of effective medicinal plant compounds that had
been comprehensively validated with lab experiment.
Preparation of Drug Molecules
The PDB file of Caffeic acid, Stigmast-7-en-3β-ol, and Quercetin
were retrieved from Pubchem (http://www.ncbi.nlm.nih.gov/
pccompound/) and Zinc database (http://zinc.docking.org/). But
later two drug compounds were not available in those databases.
Therefore, they were designed by using ACD/Chemsketch
(Yamin et al., 2002) according to their structure and then
generated their structural data file (SDF) andMol file. TheMolfile
of Rhizophorine, 1-Hydroxy-5-oxobicyclo [6.4.0] dodecane were
converted to PDB file by using Open Babel (O’Boyle et al., 2011).
Afterwards, the 3D structure optimization of these compounds
was done by the ACD/Chemsketch (Yamin et al., 2002).
Energy Minimization of Projected Model and Drawn
Molecules
Energy minimization of predicted 3D model and drawn
structure of medicinal drug compounds were calculated for the
accurate alignment which is a key requirement to link up the
structural gap between template and target. Encompass loop
rearrangements, secondary structure elements, and repacking of
core residues with YASARA (Yet Another Scientific Artificial
Reality Application) force field was performed for calculating
the relative binding free energies of homology model and drawn
structures (Krieger et al., 2009). The parameters of YASARA are
employed for the minimization of damage occurred in predicting
homology model and drawn structures with the full atomic
description. The YASARA energy functions are known to be
essential for protein stability (Sippl, 1993; Vriend and Sander,
1993; Kuszewski et al., 1997).
QSAR (Quantitative Structure Activity Relationship)
Studies
Quantitative structure activity relationship (QSAR) was
calculated for the effective drug nature properties. The structural
properties from QSAR were retrieved from Click2drug (http://
www.click2drug.org/), Zinc database (http://zinc.docking.org/),
Osiris property explorer (Sander, 2001), Molinspiration (Mishra
and Raghava, 2011), and AcTor (Judson et al., 2008).
Docking Analysis
The energy minimized homology model and the medicinal
compounds were then performed in Autodock 4.2 (Morris
et al., 2009) and AutodockVina (Trott and Olson, 2010) for
confirming the better docking analysis into the binding site.
Before initiating the docking study, all water molecules were
removed and polar hydrogen were added into minimized model
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structure. AutoDock tools 1.5.6 was used to prepare the input
pdbqt file for energy minimized envelope glycoprotein. A grid
box parameter were set in size with 40 × 40 × 40 points and
center with 168.948 × 349.143 × 240.353, and 0.5◦A for grid
spaces well. Then AutodockVina was used for all docking runs.
The same parameters for identifying the crucial amino acid
interactions with drug compounds were used for docking runs
in Autodock 4.2. In Autodock 4.2 contrast to AutodockVina,
Kollman united atom charges (Duan et al., 2003) were added to
the model structure. Autogrid was used to generate the ligand
map files for search space to comprise the ligand binding site.
To generate the set of possible conformation Lamarckian Genetic
Algorithm (LGA), which is well thought-out as one of the best for
small molecule docking studies, was used in Autodock 4.2. The
initial population size 150 was performed for the every docking
runs. The conformation was preferred with the lowest docked
energy after the docking interaction between target built model
and inhibitors. The three binding energy terms: intermolecular
energy, internal energy of ligand, and torsional free energy were
generated by Autodock 4.2. Afterwards, the final docked energy
or binding affinity was calculated from the sum of intermolecular
energy and internal energy of ligand. The molecular visualization
of protein-ligands were analyzed by PyMol (Seeliger and de.
Groot, 2010), Yasara (Krieger et al., 2009), RasMol (Roger
and James, 1995), UCSF Chimera (Pettersen et al., 2004), and
Discovery studio (Van Joolingen et al., 2005).
Analyzing Active Site
Computed Atlas of Surface Topography of proteins (CASTp;
Dundas et al., 2006) was used to identify the active regions
which further allowed to recognize crucial amino acids from
drug-protein interactions. This method allows to determine the
active residues, active sites, binding sites, and internal cavities of
protein.
Pharmacoinformatics Studies
The pharmacophore properties of our selected plant medicinal
drug molecules were carried out by the online-based and
license-agreed software. Absorption, distribution, metabolism,
excretion, and toxicity (ADME/Tox) confer the kinetics of
drug exposure and nature to the tissues and pharmacological
activity of the compounds. The Osiris property explorer (Sander,
2001), Molinspiration (Mishra and Raghava, 2011), ACToR
(Aggregated Computational Toxicology Resource; Judson
et al., 2008), admetSAR (absorption, distribution, metabolism,
excretion, and toxicity Structure-Activity Relationship database;
Cheng et al., 2012), and ACD/I-lab (Masunov, 2001) were
utilized for the calculation of ADME properties and toxic profile.
The quantitative drug likeness were calculated by the DruLiTo
software tools (Bickerton et al., 2012).
RESULTS
Analysis of the Retrieved Sequences
(Divergence and Conserved Region)
The 24 outer capsid VP4 protein of Human rotavirus A from
14 countries were retrieved and analyzed for their evolutionary
relationship. The results suggest us that they are very similar in
distance (Figure 2) analyzed by Node type (Root, Internal node,
and Leaf), Branch length, and Bootstrap values (Internal Node) of
24 strains of rotavirus (Table S1). Four conserved regions of more
than 10 amino acids were identified from the multiple sequence
alignment of 24 retrieved VP4 proteins (Figure 3, Table 1, and
Figure S1). Among the conserved regions, no. 2 and 4 included
in all the 24 strains tested, while region 1 and 3 included 23
except UK and Italy, respectively. Thereafter, the result from
globplot 2.3 identified the several disease causing region whereas
conserved region SAIIDFKTLKNLNDNYGI was also one of
them (Figure 4).
Homology Modeling and Validation
The 3D structure of VP4 protein (in this case Bangladeshi strain,
as all sequences are mostly similar) was predicted by using
the Modeller 9v11 displayed in Figure S2. Different validation
tools were employed for the structural quality assessment. The
Ramachandran plot from Procheck identified 88.6% residues in
most favored regions (Figure S3). VERIFY3D also ensure a good
3D structure of VP4 protein of rotavirus shown in Figure S4.
Antigenicity Determination of Conserved
Region
The conserved region having amino acid composition
“SAIIDFKTLKNLNDNYGI” was identified as the highest
antigenicity among the entire conserved region by multiple
sequence alignment (Table 1). This region attainted the highest
predicted antigenic score accounts to 0.9606.
T Cell Epitope Identification
NetCTL server was implemented to find T-Cell epitopes on the
conserved region of VP4 protein. The server recognizes probable
overlapping epitopes on the selected protein sequence by
utilizing neural network architecture and gives a combinatorial
score by predicting peptide MHC class-I binding based
on all MHC class-II super types, proteasomal C terminal
cleavage and TAP transport efficiency collectively. It could
allow to identify five epitopes TLKNLNDNY, AIIDFKTLK,
SAIIDFKTL, IDFKTLKNL, and KNLNDNYGI based on the
highest combinatorial score (Table 2). The set of enzymes
consisting proteasomal cleavage have the capability to cleave the
proteins to form smaller peptides. These digested peptides are
identified byMHC class 1 molecules and thenMHC class 1 forms
a complex with these digested peptides and transported to the
endoplasmic reticulum, a process further assisted by transport
TABLE 1 | Conserved region of VP4 from MSA and their antigenic score.
Conserved Amino acid Position of conserved Vaxijen score
region no. sequence regions amino acids (threshold 0.4)
1 AFRNMVYVRSL 363–373 0.2661
2 NSVTVRQDLERQL 488–500 −0.2378
3 LPLDMFSMFSGIKST 525–539 0.3204
4 SAIIDFKTLKNLNDNYGI 723–740 0.9606
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FIGURE 2 | Divergence analysis of 24VP4 proteins from 14 different countries. The neighbor joining method was used for phylogenetic tree construction for
iteratively joining clusters which are close to each other but at the same time far from all other clusters. In this method, “Kimura” protein distance measurement was
selected for the equal amino acid frequency and equal substitution rates. Bootstrap value was also shown by producing 1000 replicates for measuring the accurate
distance among the 24 strains.
TABLE 2 | The selected epitopes, on the basis of their overall score
predicted by the NetCTL server.
Number Epitopes Overall score (nm)
SU1 TLKNLNDNY 1.0488
SU2 AIIDFKTLK 1.0269
SU3 SAIIDFKTL 0.5535
SU4 IDFKTLKNL 0.4882
SU5 KNLNDNYGI 0.3519
associated proteins (TAP) before being presented to the T-cells on
the plasmamembrane of the cell. MHC class 1 binding prediction
tool from IEDB identified a number of MHC class 1 molecule
where selected five epitopes were employed. The principle of this
method is based on stabilized matrix method (SMM) that allow
to select HLA molecules to predicted epitopes utilizingIC50 nM
unit. In our study, IC50-value less than 500 nm (IC50 < 500)
was considered for the selection of the MHC-I molecules which
ascertained higher affinity to the epitopes (Table 3). Every single
epitope has individual overall score generated from MHC-
I processing efficiency tool accordingly to the proteasomal
cleavage efficiency, TAP transport efficiency, andMHC-I binding
efficiency. A higher combined score of the peptide tells us
that they are well-processed for presentation which ensures to
induce an effective immune response (Table 3). An effective
immune response is determined by the successful recognition of
epitopes by HLA molecules with strong affinity. So, a peptide
can prompt better immune response if it is interacted with
more HLA alleles. The 9-mer epitope TLKNLNDNY showed
the highest affinity for 11 MHC-1 molecules including HLA-
C∗03:03(−0.14), HLA-B∗15:01(−0.13), HLA-A∗30:02(−0.08),
HLA-B∗40:13(0.17), HLA-C∗14:02(0.31), HLA-B∗15:02(0.43),
HLA, A∗32:15(0.90), HLA-A∗68:23(1.08), HLA-B∗27:20(1.10),
HLA-A∗32:07(1.28), HLA-C∗12:03(1.61) among the five selected
epitopes. As the conserved epitopes have the greater ability
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FIGURE 3 | Conserved region in 24 different strains of Human Rotavirus A. Four conserved regions of more than 10 amino acids were found on multiple
sequence alignment. The conserved region “SAIIDFKTLKNLNDNYGI” showed higher antigenic score which allowed to predict some probable candidates for peptide
based vaccine design.
FIGURE 4 | Protein disorder regions of VP4 protein including the most antigenic conserved region. (A) The disorder regions of the whole protein sequence.
(B) The disorder region in the conserved region “SAIIDFKTLKNLNDNYGI.” Here, blue color indicates the disorder region while green color indicates the globular
domain.
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TABLE 3 | The five potential T cell epitopes, along with their interacting
MHC-I alleles and total processing score, and epitope conservancy result
from the highest antigenic conserved peptide.
Number Epitopes Interacting MHC-I allele
with an affinity of, <500nM
and the score of percentile
rank
Epitope conservancy
rate (%)
SU1 TLKNLNDNY HLA-C*12:03(1.61) 65.66
HLA-A*32:07(1.28)
HLA-B*27:20(1.10)
HLA-A*68:23(1.08)
HLA-A*32:15(0.90)
HLA-B*15:02(0.43)
HLA-C*14:02(0.31)
HLA-B*40:13(0.17)
HLA-A*30:02(−0.08)
HLA-B*15:01(−0.13)
HLA-C*03:03(−0.14)
SU2 AIIDFKTLK HLA-A*11:01(0.14), 65.36
HLA-C*12:03(0.01),
HLA-A*32:07(−0.02),
HLA-C*03:03(−0.17),
HLA-A*68:23(−0.26),
HLA-B*27:20(−0.68),
HLA-A*03:01(−0.78),
HLA-A*68:01(−0.85)
SU3 SAIIDFKTL HLA-C*03:03(1.63), 65.36
HLA-A*68:23(1.09),
HLA-A*32:07(0.97),
HLA-C*12:03(0.87),
HLA-B*27:20(0.54),
HLA-B*40:13(0.52),
HLA-A*02:50(0.52),
HLA-C*15:02(0.49),
HLA-A*32:15(0.44),
HLA-B*15:02(0.08),
HLA-A*02:17(−0.01)
SU4 IDFKTLKNL HLA-A*02:50(1.14), 65.36
HLA-B*27:20(1.05),
HLA-B*40:13(1.01),
HLA-C*12:03(0.71),
HLA-A*68:23(0.69),
HLA-A*32:07(0.61),
HLA-A*02:17(0.31),
HLA-C*14:02(0.28),
HLA-B*15:02(0.17),
HLA-C*03:03(−0.05),
HLA-B*40:02(−0.41)
SU5 KNLNDNYGI HLA-A*32:07(0.42), 63.65
HLA-A*02:50(0.36),
HLA-B*40:13(0.30),
(Continued)
TABLE 3 | Continued
Number Epitopes Interacting MHC-I allele
with an affinity of, <500nM
and the score of percentile
rank
Epitope conservancy
rate (%)
HLA-B*27:20(−0.02),
HLA-A*68:23(−0.37),
HLA-A*32:01(−0.42),
HLA-C*12:03(−0.44),
HLA-A*32:15(−0.68),
HLA-C*15:02(−0.95),
HLA-C*03:03(−1.00),
HLA-A*02:17(−1.09)
TABLE 4 | MHC–II molecules from the desired peptide epitope.
Epitope peptide MHC-II molecules
SU1 HLA-DRB1*13:02
HLA-DRB1*12:01
HLA-DRB1*03:01
HLA-DRB3*01:01
HLA-DQA1*01:01/DQB1*05:01
HLA-DRB4*01:01
HLA-DQA1*05:01/DQB1*02:01
HLA-DQA1*03:01/DQB1*03:02
to induce strong immunization, epitope conservancy was
analyzed to the possible all VP4 proteins available in databases
(both reviewed and unreviewed VP4 proteins; Table 3). The
epitope TLKNLNDNY showed the highest 65.66% conserveness
whereas the rest of four epitopes AIIDFKTLK, SAIIDFKTL,
IDFKTLKNL, and KNLNDNYGI showed 65.36, 65.36, 65.36, and
63.65% conservancy, respectively. On the basis of number of
MHC-1 molecules and epitope conservancy TLKNLNDNY was
selected to identify the MHC-II molecules (Table 4).
Population coverage is the measurement between people in
a given area and both (MHC-I and MHC-II) alleles of the
query epitopes. The 14 different countries were considered for
the analysis of population coverage by the IEDB’s population
coverage tool that generated 70.30% coverage to the Bangladeshi
people whereas highest 78.21% population coverage was found in
the Sweden. The epitopes indicated that 65.59–78.21% coverage
in Europe whereas in American region it was found 55.57–
59.19% population coverage. Moreover, Asian region showed
50.33–73.80% cumulative population coverage. The results are
shown in Figure 5.
AutoDockVina generated the binding modes of epitope
TLKNLNDNY with HLA molecules. The interacted binding
energy of the epitope TLKNLNDNY with HLA-B∗15:01 receptor
was known to be −7.4 and −7.0 kcal/mol for HLA-DR. The
epitope 3D structure and its binding site to HLA are shown
in Figure 6A (Epitope structure), Figure 6B (Epitope binds to
MHC-I), and Figure 6C (Epitope binds to MHC-II).
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B Cell Epitope Identification
To recognize the potential B-cell epitopes, a number of analysis
tools using amino scale based methodology were implemented
on conserved region. The physio-chemical properties of amino
acids from conserved region were evaluated by Kolaskar and
Tongaonkar antigenicity tool that predicted an average antigenic
propensity value of these amino acid as 1.058, with the maximum
value of 1.240 and minimum of 0.920. The threshold for
antigenic determination of conserved region was 1.00 whereas all
FIGURE 5 | Population coverage of different strains of VP4 protein. The
peptides with different HLA binding specificities will increase the population
coverage as the various HLA types are expressed at radically different
frequencies in various ethnicities. The populations were grouped upon 14
countries for our study.
values from these result >1.00 suggested as potential antigenic
determinants. The region 720–731 from the conserved region
meets the threshold value for the Kolaskar and Tongaonkar
antigenicity property (Figure 7A). Amino acid residues 723–732
of the conserved region demonstrated as surface accessibility
which is required to be an effective B cell epitope (Figure 7B).
Beta turns of a protein or region can play significant role in
prompting antigenicity as it can lead to hydrophilic properties
and surface accessibility as well (Šali et al., 1995). The region
724–732 was considered as a β-turns region from Chou and
Fasman Beta turn prediction (Figure 7C). It is speculated that the
flexibility of the peptide have strong correlation with antigenicity
(Söding, 2005). Karplus and Schulz flexibility prediction tool
identified the region 723–731 to be the most flexible (Figure 7D).
Bepipred linear epitope prediction tool was also employed in
conserved region to identify the region which could be projected
as linear B-cell epitope. And, in this case the region 726–735
was considered for linear epitope (Figure 7E). To confirm the
hydrophilic nature of a peptide region parker hydrophilicity was
also analyzed in the conserved region (Figure 7F). By cross-
referencing all the data retrieved from all B-cell properties tools,
we confirmed that the peptide sequence 725–733 from conserved
regions capable of inducing an effective immune response as B
cell epitope. The predicted T and B cell epitope was shown in
Figure 8.
Drug Selection and its Analog Preparation
Rhizophora mucronata Lamk. (Rhizophoraceae) was selected for
our study which is a mangrove’s plant found in Sundarbans
in Bangladesh and locally it is known as “Bhora.” Its size
FIGURE 6 | Docking simulation study. Structure of the predicted epitope SU1‘TLKNLNDNY’ (Red stick) (A) and visualize of docking results of SU1 with MHC-I
(HLAB*15:01); Chain A-yellow, Chain B-Bluish (B) as well as with MHC-II (HLA-DR) (C) Chain A-Yellow, Chain B-Bluish, Chain C-Blue.
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FIGURE 7 | Prediction of B-cell antigenic properties for most antigenic conserved region. SU1 showed all the antigenic criteria to be predicted as B-cell
epitope. (A) Kolaskar and Tongaonkar antigenicity prediction. (B) Emini surface accessibility prediction. (C) Chou and Fasman beta-turn prediction. (D) Karplus and
Schulz flexibility prediction. (E) Bepipred linear epitope prediction. (F) Parker hydrophilicity prediction. The x-axis and y-axis represent the sequence position and
corresponding antigenic properties score, respectively. The threshold level is 1.0 for most of the properties except for (A) (0.90) and (E) (0.19). The regions having
antigenic properties are shown in yellow color above the threshold value.
up to 15m tall, with small white flowers and long ovoid-
conical fruits (Wangensteen et al., 2013). This plant is also
found in muddy shores and tidal creeks in tropical zones of
East- and South Africa, Asia, Northeast Australia, and Central
America (Kirtikar and Basu, 1935). The bark and leaves are
traditionally used in diarrheal patient. Quercetin and caffeic acid,
isolated compounds from bark, appeared to have the highest
activity as antidiarrheal (Rohini and Das, 2010).Whereas isolated
compounds, Stigmast-7-en-3β-ol, Rhizophorine, 1-Hydroxy-5-
oxobicyclo [6.4.0] dodecane, with methanol extracts from leaves
were also demonstrated as antidiarrheal (Puspitasar et al., 2012).
The 2D structure of these molecules were depicted in Figure 9.
Energy Minimization Analysis
YASARA program was used in refining physical realism,
stereochemistry, and side-chain accurateness in homology
modeling and designed molecules. This program yields
the energy (START vs. END) that ensures accuracy of
modeled protein and designed molecules (Figure S5). The
End energy of homology modeling was −383,578.5 kJ/mol
compared to START energy −101,952.5 kJ/mol, revealed
that the model protein is more accurate than the prior
modeled protein. In the case of drawn molecules the energy
comparison from the START energy Rhizophorine (12,454.4
kJ/mol) and 1-Hydroxy-5 oxobicyclo[6.4.0]dodecane (4473.9
kJ/mol) to END energy is Rhizophorine (471.5 kJ/mol)
and 1-Hydroxy-5 oxobicyclo[6.4.0]dodecane (210.2 KJ/mol)
(Figure S5).
Docking and Active Site Analysis
The two most convenient docking tools Autodock 4.2 and
AutodockVina of MGL 1.5.6 were employed to analyze the
protein–drug interactions. All docking run was performed
between the modeled protein and drug compounds with
the set of docking parameters mentioned in Materials and
Methods Section. The docking energy of these drug molecules
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FIGURE 8 | Selected region for T-cell and B-cell epitope from built model. Black region indicates the SU1 epitope region of 3-D structure of VP4 protein (A).
Position of SU1 epitope in linear amino acid sequence of VP4 protein (B).
in AutoDockVina (Caffeic acid: −6.7 kJ/mol, Quercetin: −8.3
kJ/mol, Stigmast-7-en-3β-ol: −7.24 kJ/mol, Rhizophorine: −7.7
kJ/mol, 1-Hydroxy-5-oxobicyclo [6.4.0] dodecane: −8.0 kJ/mol)
and AutoDock 4.2 (Caffeic acid: −5.99 kJ/mol, Quercetin: −7.24
kJ/mol, Stigmast-7-en-3β-ol:−6.67 kJ/mol, Rhizophorine:−6.88
kJ/mol, 1-Hydroxy-5-oxobicyclo [6.4.0] dodecane: −7.3 kJ/mol)
tabulated in Table 5 which suggest the higher binding affinity.
These analyses showed that the drug molecules bind into
the binding site shown in Figure 10. The analysis of binding
site also revealed that the interacting residues bind into the
binding site shown in Figure 11A. And all the residues are
the active residues of binding site shown in Figure 11B.
It was interesting to observe that all drug compounds
which were analyzed for this study interacted with the most
common three residues (Val-61, Leu-237, Glu-292) shown in
Table 5.
QSAR and Pharmacoinformatics Analysis
The outcomes from OSIRIS property explorer, ACToR and
Molinspiration have been tabulated to analyze the compounds
quantitative structural activity relationship and structural
polarity (Table 6) which confirm them as possible drug
candidates. In this study we also verified the overall toxicity
and ADME (Absorption, Distribution, metabolism, Excretion)
using admetSAR, ACD/I-lab, AcTor and Osiris program.
admetSAR and ACD/I-lab prediction methods involves Human
Intestinal Absorption (HIA), Skin permeability, Blood-Brain
Barrier distribution (LogBB), Caco-2 cell permeability, Volume
of distribution, CYP450 2C9 substrate, and inhibitors. The
Osiris program was used for the generation of toxicity
profile of selected compounds. The result of these studies
is given in Table 7. The DruLiTo software suggests that the
medicinal plant drug compounds have higher drug likeness
to be expected as antidiarrheal drug. The drug likeness
of Caffeic acid (0.561), Quercetin (0.458), Stigmast-7-en-3β-
ol(0.742), Rhizophorine(0.804), 1-Hydroxy-5 oxobicyclo[6.4.0]
dodecane(0.614) (Figure 12) as well as oral bioavailabilty
(Figure 13 and Table 6) confirm their drug efficacy. Besides these
drug compounds also confirmed that there are no mutagenic,
irritative, reproductive toxicity, and carcinogenic profile.
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FIGURE 9 | Two dimensional (2D) structure of selected compounds from medicinal plant Rhizophora mucronata Lamk. (A) Caffeic acid, (B) Quercetin, (C)
Rhizophorine, (D) Stigmast-7-en-3β-ol, (E) 1-Hydroxy-5 oxobicyclo[6.4.0] dodecane.
TABLE 5 | Docking result of medicinal plant compounds.
Inhibitors Residues name Docking energy/binding affinity Inhibitor constant Ligand Intermolecular Electrostatic
(Kcal/mol) Ki (µm) efficieny energy energy
AutodockVina Autodock 4.2
Caffeic acid Val-61, Asn-231, Val-232,
Pro-234, Ser-236, Leu-237,
Ser-291, Glu-292, Phe-325,
Arg-340
−6.7 −5.99 40.44 0.92 −6.92 −1.65
Quercetin Asn-56, Val-61, Glu-227,
Asn-231, Val-232, Pro-234,
Ser-236, Leu-237, Ile-281,
Ser-291, Glu-292, Ile-293,
Phe-325, Arg-340
−8.3 −7.42 63.87 0.9 −7.17 −1.22
Stigmast-7-en-3β-ol Asn-56, Asp-57, ser-58, Val-61,
Ile-226, Val-233, Leu-237,
Ser-279, Ile-293, Ser-294
−7.24 −6.67 49.33 0.7 −5.99 −2.43
Rhizophorine Asn-56, Asp-57, Thr-59, Val-61,
Glu-227, Asn-231, Val-233,
Ile-237, Glu-292
−7.7 −6.88 27.48 0.55 −6.33 −2.34
1-Hydroxy-5-oxobicyclo
[6.4.0]dodecane
Val-61, Glu-227, Val-233,
Leu-235, Ile-281, Ser-291,
Glu-292, Arg-340
−8.0 −7.3 51.48 0.63 −5.49 −1.54
DISCUSSION
Now a days, developing country is being more sufferer as the
new diseases and severity of diseases are evolving along with new
viruses in parallel to advancement of the medical technology.
However, medical science has always tried to cope up with the
problems of replicating disease. Human rotavirus infection is one
of the reasons of fatalities in humans in a number of countries like
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FIGURE 10 | Drug compounds binding amino acid residues of VP4 3D model. (A) Caffeic acid, (B) Quercetin, (C) Rhizophorine E, (D) Stigmast-7-en-3β-ol, (E)
1-Hydroxy-5-oxobicyclo [6.4.0] dodecane.
TABLE 6 | QSAR properties of medicinal plant compounds.
Ligand properties Caffeic acid Quercetin Stigmast-7-en-3β-ol Rhizophorine 1-Hydroxy-5-oxobicyclo [6.4.0]dodecane
Molecular weight(g/mol) 180.16 302.24 414.72 203.24 210.32
No. of H donor 3 5 1 2 1
No. of H acceptor 4 7 1 3 2
No. of rotatable bonds 2 1 6 3 0
No. of hydrogen bond 7 12 2 5 3
logP 0.888 1.834 11.785 1.265 −1.568
TPSA 77.75 131.35 20.23 53.09 37.30
unwQED 0.655 0.467 0.617 0.841 0.624
Oral bioavailability Between 30 and 70% <30% Between 30 and 70% More than 70% More than 70%
Bangladesh, India, Thailand, USA, Australia, UK, etc. To cure
this type of diseases both vaccines and drugs are compulsory.
However, only wet lab approach couldn’t allow the faster method
for drug and vaccine design.
The advancement of new vaccine is very important to resist
this deadly virus. Recently, bioinformatics tools have been proved
very effective to design peptide based vaccine to target a specific
protein. Epitope-based vaccine designing against rhinovirus
(Lapelosa et al., 2009) and dengue virus (Chakraborty et al.,
2010) have already been recommended. In spite of being an
acquainted concept, epitope-based vaccine designing hasn’t yet
been utilized against VP4 protein. Although vaccine designing
based on B cell immunity is a common concept, but both T
cell and B cell epitope are encouraged now a days as both of
them produce strong immune response (Shrestha and Diamond,
2004). In this study, we have used different bioinformatics tools
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FIGURE 11 | Interactions of drug compounds with the VP4 protein. (A) Binding site of drug compounds in VP4 protein. Circled area depicts the binding site of
VP4 protein. (B) Active site residues (Blue) of VP4 protein model.
TABLE 7 | ADMET properties of the medicinal plant compounds.
Properties Caffeic acid Quercetin Stigmast-7-en-3β-ol Rhizophorine 1-Hydroxy-5-oxobicyclo [6.4.0]dodecane
ABSORPTION
Renal organic cation transporter 0.9387 0.9310 0.7866 0.9131 0.8457
Blood brain barrier 0.6322 0.5711 0.9820 0.9847 0.9692
Human intestinal absorption 0.9392 0.9650 1.0000 1.0000 1.0000
Caco-2 permeability 0.5693 0.8957 0.8147 0.5403 0.8182
DISTRIBUTION
DBP (%PPB) 46.57% 93.43% 99.52% 92.82% 52.94%
Blood brain distribution (logBB) −0.16 0.53% −0.02 −0.74 0.44
Volume of distribution (Vd) 0.31 L/k 0.6 L/kg 6.27 L/kg 0.31 L/kg 1.53 L/kg
METABOLISM
CYP450 2C9 substrate 0.8014 0.7898 0.8219 0.7614 0.7915
CYP450 2C9 inhibitor 0.9071 0.5823 0.8613 0.8025 0.9021
TOXICITY
Violation No No No No No
Mutagenecity No No No No No
Tumorogenecity No No No No No
Irritating effects No No No No No
Reproductive effects No No No No No
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FIGURE 12 | Quantitative estimation of drug likeness. Rhizophorine
showed the highest score of drug likeness (0.804) compared to other
compounds.
to predict both B and T cell epitopes to confer better immunity in
rotavirus.
To develop an epitope based vaccine against rotavirus effective
for the globe we have analyzed the distance among 24 available
alleles of VP4 protein available from 14 different countries. As a
consequence of small distances among the allele, four conserved
regions could be identified among the 24VP4 protein alleles
(Figures 2, 3, Table 1 and Figure S1). The conserved region
showing the highest antigenicity (antigenic score 0.9606) was
considered as the potent region (SAIIDFKTLKNLNDNYGI)
of epitope prediction (Table 1). Among the predicted most
potent five T cell epitopes derived from conserved region
4, peptide region 725–733 “TLKNLNDNY” termed as SU1
showed the highest NetCTL score (1.048) as well as the highest
conservancy rate 65.66% (Table 2). SU1 epitope is expected to
provide the protection broadly as this epitope is conserved
against all the available rotavirus strains. The specific high
affinity binding of SU1 with 11 HLA-I as well as HLA DR
and DQ molecules is anticipated as the efficiency of this
epitope vaccine’s precise interaction with HLA alleles. It is
to be noted that more interactions with MHC-1 molecules
were observed when higher concentrations (>500 nM) were
considered (data not shown; Tables 3, 4). To confirm the
binding affinity, SU1 epitope was docked to both MHC-I
and MHC-II allele HLA-B∗15:01 and HLA-DR, respectively
(Figure 6). The docking analysis confirmed the SU1 epitope
binding with the MHC-alleles. The selected alleles responsible
for higher affinity by SU1 were found to be covered for at
least half of the population of the corresponding 14 countries
(Figure 5). We have also searched for B cell epitopes in the
conserved region as B cell epitopes can induce both primary
and secondary immunity. All the six set of tools also confirmed
FIGURE 13 | Oral bioavailability rate of compounds. Rhizophorine and
1-Hydroxy-5-oxobicyclo [6.4.0] dodecane indicated higher oral bioavailability
rate (70–100%) than the other plant medicinal drug compounds.
the presence of antigenicity, beta turns, linearity, flexibility,
accessibility and hydrophillicity of SU1 as a potent B-cell
epitope. According to these results that the vaccine would be
effective for a vast population throughout a wide geographical
region.
The chronic stage of the rotavirus infection can last for
long times. Therefore, for minimization or complete elimination
of chronic symptoms caused by the infection, a therapeutic
agent is required. Furthermore, a universal drug is essential
to completely eradicate the rotavirus infection. If mutation in
the virus causes reduction of the effectiveness of the vaccine,
the drug may work alongside to diminish the symptoms
faster. In the worst case, sudden rotavirus outbreak in a non-
vaccinated area vaccination might become outdated. Only post-
therapeutic measure or drug would be effective until new
vaccine kicks in. In the present study along with pre therapy
vaccine development we also predicted the active sites on the
highest antigenic protein of the rotavirus and subsequently
predicted the novel inhibitors of the protein to generate post
therapy.
To have the better therapeutic strategies against rotavirus
induced diarrhea some novel medicinal drug compounds
(Figure 9) were analyzed by bioinformatics analysis.
Experimental data suggest that the plant medicinal compounds
have considerable values of antidiarrheal activities but their exact
modes of action yet to be investigated. Drug design studies focus
on drug-protein interactions and these interactions are usually
considered effective when found in active pocket of binding
site of the protein (Hossain et al., 2016). According to this
hypothesis, modeled VP4 protein and selected plant compounds
were investigated for their appropriate binding. With two most
suitable docking programs, we have identified their interacting
residues as Val-61, Leu-237, and Glu-292. The ligand–receptor
interactions Val-61 were found in all the drug compounds. All
of these interacting amino acids are placed in the active pocket
of the VP4 protein (Figures 10, 11). The drug nature of the
medicinal compounds were confirmed by acceptable QSAR
(Quantitative structure activity relationship) and ADMET/Tox
properties (Tables 6, 7). Among the ADMET properties,
Stigmast-7-en-3β-ol, Rhizophorine and 1-Hydroxy-5-oxobicyclo
[6.4.0] dodecane show the same human intestinal absorption rate
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(1.000) than the Caffeic acid (0.9392) and Quercetin (0.9650).
The drugs effectiveness also assured as no signs to cross Blood
Brain barrier observed. As expected, blood brain distribution
of the drug compounds are less than zero except Quercetin
(0.53). Volume of distribution of drugs is quite good into body
as the score is ranging from 0.31 to 6.27 l/kg. The satisfactory
metabolic score (0.5823–0.9071) was perceived for five drug
compounds. And no toxic effect would be expected from
these compounds treated to the rotaviral mediated diarrheal
patient.
Also the higher drug likeness (Figure 12) and oral
bioavailability (Figure 13) of all medicinal drug compounds
support their effectiveness as antidiarrheal drugs. Thus, these
molecules could be possible inhibitory agents of VP4 protein
against rotavirus A.
However, experimental validations for these predicted
epitopes are indeed necessary for their practical application.
Experiments for synthesized peptides might include T-cell
proliferation and flowcytometry for activated B-cell with specific
markers (Geluk et al., 2000, 2009; De Groot et al., 2001; McMurry
et al., 2007; Davila et al., 2012; Commandeur et al., 2014; Khan
et al., 2014). For the drug discovery, the suggested drugs have to
be synthesized to test the efficacy in animal model experiment.
Thereafter, both preclinical and clinical study should be done
before the drug marketing.
Finally, after experimental validation the suggested SU1
peptide for T and B-cell epitope may efficiently be used for
the improvement of peptide vaccine to provoke an absolute
immune response against VP4 protein of rotavirus. Moreover,
identification of novel plant medicinal compounds are expected
to be successful inhibitor against the rotavirus.
CONCLUSION
We have identified a potential peptide region from VP4 protein
of human rotavirus A for vaccine design which is likely to prompt
both T and B-cell mediated immune responses. The study
was performed by utilizing computational approaches based on
sequence conservancy, antigenicity and its allelic interactions.
In addition, we have proposed compounds from medicinal
plant Rhizophora mucronata Lamk. which might be effective
against rotavirus A as antidiarrheal drugs. Absence of accurate
investigational disease model, however, can hinder to confirm
this in silico study for rotavirus. So it is therefore to be needed
suitable animal model experiments for the validation of the
proposed epitopes and drugs.
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